Program
Adalimumab
Also written as “adalimumab”, “MSB11022” and “M923”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.
Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 620 open or running | phase 4since Sep 13, 2005 | Nov 1, 2002 | none ahead |
| AbbVie | 543 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | Sep 2027phase 2 · NCT06257875 |
| Alvotech Swissits history only | 60 open or running | phase 3since Feb 5, 2019 | Jun 8, 2018 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Fresenius Kabiits history only | 40 open or running | phase 3since Jan 17, 2016 | Jan 17, 2016 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Mar 31, 2016 | Mar 16, 2015 | none ahead |
| Cinnagenits history only | 20 open or running | phase 3since May 24, 2017 | May 24, 2017 | none ahead |
| Sino Biopharmaceuticalits history only | 22 open or running | phase 4since Apr 8, 2026 | Apr 8, 2026 | Apr 2028phase 4 · NCT07529925 |
| Takedaits history only | 20 open or running | phase 4since May 5, 2016 | Mar 15, 2015 | none ahead |
| Viatrisits history only | 20 open or running | phase 3since Nov 9, 2015 | Jun 3, 2015 | none ahead |
| care-arthritis-ltdits history only | 10 open or running | phase 2since Feb 24, 2015 | Feb 24, 2015 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Sep 18, 2019 | Sep 18, 2019 | none ahead |
| LG Chemits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| mabscale-llcits history only | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| National Resilienceits history only | 10 open or running | phase 3since Jan 10, 2021 | Jan 10, 2021 | none ahead |
| prestige-biopharma-limitedits history only | 11 open or running | phase 1since Oct 1, 2021 | Oct 1, 2021 | Jun 2027phase 1 · NCT05108259 |
| Samsung Bioepisits history only | 10 open or running | phase 1since Aug 13, 2020 | Aug 13, 2020 | none ahead |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Sep 13, 2005.
- Jul 7, 20142 phase 3 studiesNCT02185014, NCT02196701
- Jul 22, 2014Phase 4 study in Arthritis, RheumatoidNCT02198651 · 149 enrolled · United States, Australia, Austria and more
- Jul 14, 2015Phase 3 study in Crohn DiseaseNCT02499783 · 205 enrolled
- Aug 20, 2015Phase 3 study in PsoriasisNCT02533375 · 10 enrolled
- Dec 10, 20152 phase 3 studiesNCT02629159, NCT02632175
- Jun 20, 20162 phase 4 studiesNCT02808975, NCT02814175
- Sep 7, 2016Phase 4 study in Axial SpondyloarthritisNCT02897115 · 22 enrolled
- Sep 14, 2016Phase 3 study in Hidradenitis SuppurativaNCT02904902 · 15 enrolled · Japan
- Oct 12, 2017Phase 3 study in Pyoderma GangrenosumNCT03311464 · 22 enrolled · Japan
- Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923
- Jan 29, 2019Phase 2 study in Arthritis, RheumatoidNCT03823391 · 48 enrolled · United States, Germany, Hungary and more
- Jun 8, 2022Phase 4 study in Non-infectious Intermediate Posterior- or Pan-uveitisNCT05414201 · 87 enrolled · China
- Apr 4, 2023Phase 3 study in Arthritis, RheumatoidNCT05814627 · 487 enrolled · United States, Argentina, Belgium and more
- Oct 2, 2023Phase 2 study in Colitis, UlcerativeNCT06257875 · 156 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 3 study in Arthritis, JuvenileNCT06100744 · 40 planned · United States, Australia, Canada and more
Ahead
- Sep 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT06257875
TargetBeta
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| CHS-1420rule | nanjing-king-friend-biochemical-pharmaceutical-co-ltd | phase 3 | 2 |
| brivekimig | Sanofi | phase 2 | 6 |
| Hadlimarule | biora-therapeutics-inc | phase 1 | 1 |
Studies
All 54 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more | 3 | Recruiting | Sep 2026 | 40 |
| NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Active, not recruiting | Sep 2027 | 156 |
| NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Jul 15, 2026 | 487 |
| NCT05414201Non-infectious Intermediate Posterior- or Pan-uveitis · China | 4 | Completed | Jun 10, 2024 | 87 |
| NCT03823391Arthritis, Rheumatoid · United States, Germany, Hungary and more | 2 | Completed | Apr 8, 2020 | 48 |
| NCT03311464Pyoderma Gangrenosum · Japan | 3 | Completed | Aug 20, 2019 | 22 |
| NCT02904902Hidradenitis Suppurativa · Japan | 3 | Completed | Sep 1, 2017 | 15 |
| NCT02897115Axial Spondyloarthritis | 4 | Terminated | Dec 21, 2017 | 22 |
| NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more | 4 | Completed | Sep 23, 2019 | 246 |
| NCT02808975Hidradenitis Suppurativa · United States, Belgium, Canada and more | 4 | Completed | May 16, 2019 | 206 |
| NCT02632175Colitis, Ulcerative · United States, Japan, Poland and more | 3 | Completed | Apr 8, 2025 | 59 |
| NCT02629159Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 27, 2017 | 1,629 |
| NCT02533375Psoriasis | 3 | Completed | Sep 15, 2016 | 10 |
| NCT02499783Crohn Disease | 3 | Completed | May 19, 2017 | 205 |
| NCT02198651Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | May 3, 2018 | 149 |
| NCT02196701Psoriasis | 3 | Completed | Mar 17, 2017 | 46 |
| NCT02185014Crohn Disease | 3 | Completed | Nov 3, 2017 | 252 |
| NCT02148718Crohn Disease | 4 | Completed | Aug 2016 | 100 |
| NCT02065622Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Completed | Sep 5, 2019 | 952 |
| NCT02065570Crohn Disease · United States, Austria, Belgium and more | 3 | Completed | Jan 30, 2020 | 514 |
| NCT02065557Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | Feb 7, 2020 | 101 |
| NCT02016482Nail Psoriasis | 3 | Completed | Oct 2015 | 217 |
| NCT02015793Crohn Disease | 2 | Completed | Feb 2015 | 30 |
| NCT01958827Crohn Disease | 3 | Completed | Mar 2015 | 28 |
| NCT01808118Axial Spondyloarthritis | 3 | Completed | Feb 21, 2017 | 673 |
| NCT01752855Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | Oct 2013 | 88 |
| NCT01646073Psoriasis · China | 3 | Completed | Dec 2013 | 425 |
| NCT01712178Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | May 2013 | 100 |
| NCT01644396Moderate to Severe Plaque Psoriasis · Russian Federation | 4 | Completed | Sep 2013 | 50 |
| NCT01561313Arthritis, Rheumatoid · Belgium, Czech Republic | 2 | Completed | Nov 2012 | 64 |
| NCT01550965Colitis, Ulcerative | 3 | Completed | Apr 2015 | 463 |
| NCT01635764Hidradenitis Suppurativa | 3 | Completed | Aug 2016 | 508 |
| NCT01502423Arthritis, Rheumatoid · Australia, Canada, Germany | 2 | Completed | Nov 2012 | 61 |
| NCT01468233Hidradenitis Suppurativa | 3 | Completed | Apr 2014 | 326 |
| NCT01468207Hidradenitis Suppurativa | 3 | Completed | Jan 2014 | 307 |
| NCT01265823Psoriasis · Mexico | 4 | Completed | Feb 2012 | 150 |
| NCT01251614Plaque Psoriasis | 3 | Completed | Dec 2013 | 114 |
| NCT01243671Intestinal Behçet's Disease · Japan | 3 | Completed | Mar 2012 | 20 |
| NCT01235689Crohn Disease | 3 | Completed | Nov 3, 2016 | 252 |
| NCT01185301Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | Sep 2012 | 395 |
| NCT01185288Arthritis, Rheumatoid · United States, Puerto Rico | 4 | Completed | Jan 2013 | 309 |
| NCT01166282Arthritis, Juvenile | 3 | Completed | Nov 2012 | 46 |
| NCT01162421Arthritis, Rheumatoid | 4 | Completed | Jul 2015 | 77 |
| NCT01148225Uveitis | 3 | Completed | May 21, 2018 | 424 |
| NCT01138657Uveitis | 3 | Completed | Jul 2014 | 239 |
| NCT01124838Uveitis | 3 | Completed | May 2015 | 261 |
| NCT01064856Peripheral Spondyloarthritis | 3 | Completed | Aug 2011 | 165 |
| NCT00939003Axial Spondyloarthritis · United States, Australia, Belgium and more | 3 | Completed | Feb 2011 | 192 |
| NCT00853099Colitis, Ulcerative · Japan | 3 | Completed | May 2011 | 274 |
| NCT00775437Arthritis, Juvenile | 3 | Completed | Mar 2013 | 32 |
| NCT00686374Crohn Disease | 3 | Completed | Apr 4, 2017 | 100 |
| NCT00650156Arthritis, Rheumatoid · China | 1 | Completed | Oct 2007 | 24 |
| NCT00573794Colitis, Ulcerative | 3 | Completed | Dec 2016 | 592 |
| NCT00195663Arthritis, Rheumatoid · United States, Australia, Austria and more | 3 | Completed | Apr 2004 | 799 |
How it is read
Names in the registry
- “Adalimumab”, 69 entries
- “adalimumab”, 63 entries
- “MSB11022”, 3 entries
- “M923”, 3 entries
- “Humira (adalimumab)”, 3 entries
Codes read as this program: AVT02.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 45 studies
- Psoriasis, 25 studies
- Crohn Disease, 23 studies
- Colitis, Ulcerative, 9 studies
- Hidradenitis Suppurativa, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.